Related Experiment Video

Updated: Sep 7, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

842

Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer

Ruo-Fei Sun1,2, Na He1,2, Geng-Yuan Zhang1,2

  • 1Department of General Surgery, Lanzhou University Second Hospital, Lanzhou, People's Republic of China.

Current Cancer Drug Targets
|June 17, 2022
PubMed
Abstract

Insights

Combining KIF11 and KIF15 inhibitors shows promise for gastric cancer (GC) treatment. This novel strategy targets key proteins involved in cell division, offering a potential new therapeutic avenue for GC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Gastric cancer (GC) requires novel therapeutic strategies for improved outcomes.
  • Kinesin family members KIF11 and KIF15 are crucial for bipolar spindle assembly and chromosome segregation.
  • Their cooperative function suggests a potential therapeutic target in GC.

Purpose of the Study:

  • To evaluate the combined therapeutic effect of KIF15 inhibitor KIF15-IN-1 and KIF11 inhibitor ispinesib in gastric cancer.
  • To investigate the role of KIF11 and KIF15 in GC cell proliferation and sensitivity to inhibition.

Main Methods:

  • Validated KIF11 and KIF15 expression in GC tissues via immunohistochemistry and immunoblotting.
  • Determined the impact of KIF11 or KIF15 knockout on GC cell proliferation.
  • Investigated the synergistic effects of KIF11 and KIF15 inhibitors in vitro and in vivo.

Main Results:

  • KIF11 and KIF15 were overexpressed in GC tissues compared to normal tissues.
  • Knockout of KIF11 or KIF15 reduced GC cell proliferation and clonogenic potential.
  • Combined inhibition of KIF11 and KIF15 demonstrated synergistic antitumor effects in vitro and in vivo.

Conclusions:

  • Combined inhibition of KIF11 and KIF15 represents a potential effective therapeutic strategy for gastric cancer.
  • Targeting KIF11 and KIF15 offers a novel approach to enhance GC treatment efficacy.
Keywords:
Gastric cancerKIF11KIF15KIF15-IN-1inhibitionispinesib

More Related Videos

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

2.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
259
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K